Inspira™ prepares production in response to spread of respiratory virus in China Investing.com

admin6 hours ago

0 0 3 minutes read

RA’ANANA, Israel, January 10, 2025 /PRNewswire/ — Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (“Inspira” or the “Company”), a leader in life support technology innovation, announced today that it is preparing to potentially increase production of its INSPIRA™ ART100 device. This strategic readiness comes in light of the recent outbreak of human metapneumovirus (hMPV) in the Chinawhich highlighted the growing need for advanced respiratory care technologies globally.

Inspira is already in discussions with leading providers in the affected regions to assess demand for advanced respiratory solutions and the introduction of the INSPIRA™ ART100 device, ensuring rapid response capabilities in the event of increased demand.

As global health authorities monitor the hMPV outbreak, Inspira™ believes it is well positioned to meet the potentially increased demand for advanced respiratory support systems. Inspira works closely with suppliers to secure the necessary raw materials and components to meet potential spikes in demand. The company is monitoring the hMPV situation globally and is working to adjust production plans as needed.

“Although hMPV is not a new virus, and experts indicate that the current outbreak is part of normal seasonal patterns, Inspira believes we are ready,” said Dagi Ben-Noon, CEO of Inspira. “Our increased manufacturing capacity will help ensure healthcare providers have access to vital respiratory care equipment should the need arise.”

Inspira emphasizes that its preparedness measures are preventive and aligned with the company’s commitment to global health preparedness. The company will work closely with health authorities in the affected regions and adapt its plans based on the evolving situation.

Inspira™ Technologies OXY BHN Ltd.

Inspira Technologies is an innovative medical technology company in the field of life support and respiratory treatment. The company has developed a revolutionary technology of enhanced breathing (INSPIRA™ ART), a revolutionary device poised to revolutionize the $19 billion mechanical ventilation market. With 20 million ICU patients with acute respiratory failure each year, many of whom rely on mechanical ventilators, INSPIRA ART offers a potential alternative by elevating and stabilizing depleting oxygen saturation levels in ventilator-free minutes, keeping patients awake during treatment. INSPIRA ART is equipped with an attachable HYLA™ blood sensor, real-time continuous blood monitoring technology, with the aim of alerting doctors to changes in the patient’s condition without the need for periodic real blood samples, with the aim of supporting doctors in making an informed decision.

In June i July 2024or INSPIRA company^™ The ART100 system has received FDA 510(k) clearance for use in CBP procedures, along with Israeli AMAR certification for extracorporeal membrane oxygenation and Cardiopulmonary bypass procedures.

The company’s other products and technologies, including INSPIRA ART also known as INSPIRA™ ART500 or Gen 2, INSPIRA™ Cardi-ART Portable Modular Device, VORTX™ Oxygen Delivery System and HYLA™ Blood Sensor, are currently being designed and developed, and have not yet been tested or used on humans nor approved by any regulatory body.

For more information, please visit our corporate website at https://inspira-technologies.com

Forward-Looking Statement Disclaimer This press release contains express or implied forward-looking statements pursuant to s OUR Federal securities laws. These forward-looking statements are based only on the current expectations of the Company’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the company uses forward-looking statements when it talks about the growing need for advanced respiratory care technologies and its ability to adjust its plans to respond quickly to increased demand. These forward-looking statements and their implications are based solely on the current expectations of the Company’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly announce any changes to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s Annual Report on Form 20-F for the fiscal year just ended December 31, 2023filed in US Securities and Exchange Commission (“SEC“), which is available at The SECs website at www.sec.gov.

Contact: Inspira Technologies “Relations with the media
Email: info@inspirao2.com
Phone: +972-9-9664485

MRK-ARS-113

Logo: https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg

Source link